Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 5/2012

01-05-2012 | Original Research Article

Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples

Authors: Mr Peter M. Wahl, MLA, MS, Joshua J. Gagne, Thomas E. Wasser, Debra F. Eisenberg, J. Keith Rodgers, Gregory W. Daniel, Marcus Wilson, Sebastian Schneeweiss, Jeremy A. Rassen, Amanda R. Patrick, Jerry Avorn, Rhonda L. Bohn

Published in: Drug Safety | Issue 5/2012

Login to get access

Abstract

Background: Several efforts are under way to develop and test methods for prospective drug safety monitoring using large, electronic claims databases. Prospective monitoring systems must incorporate signalling algorithms and techniques to mitigate confounding in order to minimize false positive and false negative signals due to chance and bias.
Objective: The aim of the study was to describe a prototypical targeted active safety monitoring system and apply the framework to three empirical examples.
Methods: We performed sequential, targeted safety monitoring in three known drug/adverse event (AE) pairs: (i) paroxetine/upper gastrointestinal (UGI) bleed; (ii) lisinopril/angioedema; (iii) ciprofloxacin/Achilles tendon rupture (ATR). Data on new users of the drugs of interest were extracted from the HealthCore Integrated Research Database. New users were matched by propensity score to new users of comparator drugs in each example. Analyses were conducted sequentially to emulate prospective monitoring. Two signalling rules — a maximum sequential probability ratio test and an effect estimate-based approach — were applied to sequential, matched cohorts to identify signals within the system.
Results: Signals were identified for all three examples: paroxetine/UGI bleed in the seventh monitoring cycle, within 2 calendar years of sequential data; lisinopril/angioedema in the second cycle, within the first monitoring year; ciprofloxacin/ATR in the tenth cycle, within the fifth year. Conclusion: In this proof of concept, our targeted, active monitoring system provides an alternative to systems currently in the literature. Our system employs a sequential, propensity score-matched framework and signalling rules for prospective drug safety monitoring and identified signals for all three adverse drug reactions evaluated.
Literature
1.
2.
Trifiró G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoe-pidemiol Drug Saf 2009; 18: 1176–84CrossRef
3.
Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323–37PubMedCrossRef
4.
Avorn J. In defense of pharmacoepidemiology: embracing the yin and yang of drug research. N Engl J Med 2007; 357: 2219–21PubMedCrossRef
5.
Platt R, Wilson M, Chan KA, et al. The new Sentinel Network: improving the evidence of medical-product safety. N Engl J Med 2009; 361: 645–7PubMedCrossRef
6.
Platt R, Madre L, Reynolds R, et al. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 2008; 17: 1175–82PubMedCrossRef
7.
Brown JS, Moore KM, Braun MM, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. Med Care 2009; 47: 1251–7PubMedCrossRef
8.
Brown JS, Kulldorff M, Chan A, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 2007; 16: 1275–84PubMedCrossRef
9.
Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019–27PubMedCrossRef
10.
Behrman RE, Benner JS, Brown JS, et al. Developing the sentinel system: a national resource for evidence development. N Engl J Med 2011; 364(6): 498–9PubMedCrossRef
11.
Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010; 153(9): 600–6PubMed
12.
Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59–64PubMedCrossRef
13.
de Abajo FJ, Rodriguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106–9PubMedCrossRef
14.
de Abajo FJ, Montero D, Rodriguez LAG, et al. Antide-pressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98: 304–10PubMedCrossRef
15.
Dunn NR, Pearce GL, Shakir SAW. Association between SSRIs and upper gastrointestinal bleeding: SSRIs are no more likely than other drugs to cause such bleeding. BMJ 2000; 320: 1405–6PubMedCrossRef
16.
Layton D, Clark DWJ, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57: 167–76PubMedCrossRef
17.
Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 2008; 17:328–35PubMedCrossRef
18.
Meijer WEE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367–70PubMedCrossRef
19.
Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22: 175–81PubMedCrossRef
20.
van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323: 655–8PubMedCrossRef
21.
Vidal X, Ibanez L, Vendrell L, et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008; 31: 159–68PubMedCrossRef
22.
Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicenter retrospective analysis. Aliment Pharmacol Ther 2006; 23: 937–44PubMedCrossRef
23.
Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmaceopidemiol and Drug Saf 2010; 19(6): 596–603CrossRef
24.
Raiford DS, Pérez Gutthann S, García Rodríguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 1996; 7: 101–4PubMedCrossRef
25.
Andrade SE, Gurwitz JH, Chan KA, et al. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. J Clin Epidemiol 2002; 55: 310–3PubMedCrossRef
26.
Angioedema due to ACE inhibitors: common and inadequately diagnosed. Prescrire Int 1998; 7 (35): 92–3
27.
Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48(3): 374–84PubMedCrossRef
28.
Piller LB, Ford CE, Davis BR, et al. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2006; 8(9): 649–56CrossRef
29.
Vleeming W, van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 1998; 18(3): 171–88PubMedCrossRef
30.
Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf 2006; 15(11): 784–92PubMedCrossRef
31.
Corrao G, Zambon A, Bertu L, et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf 2006; 29(10): 889–96PubMedCrossRef
32.
Sode J, Obel N, Hallas J, et al. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Pharmacol 2007; 63(5): 499–503PubMedCrossRef
33.
Van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48(3): 433–7PubMedCrossRef
34.
Van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324(7349): 1306–7PubMedCrossRef
35.
Van der Linden PD, Sturkenboom MC, Herings RM, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163(15): 1801–7PubMedCrossRef
36.
Yee CL, Duffy C, Gerbino PG, et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002; 21(6): 525–9PubMedCrossRef
37.
Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. 2001 Apr 22–25; SAS Institute Inc, Cary (NC)
38.
Li L, Kulldorff M. A conditional maximized sequential probability ratio test for pharmacovigilance. Stat Med 2010; 29(2): 284–95PubMed
39.
Brown JS, Kulldorff M, Petronis KR, et al. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations. Pharmacoepidemiol Drug Saf, 2009; 18: 226–34PubMedCrossRef
40.
Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007; 45 (10 Suppl. 2): S89–95PubMedCrossRef
41.
Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10(6): 483–6PubMedCrossRef
42.
Selvin S. Statistical analysis of epidemiologic data. 3rd ed. New York: Oxford University Press, 2004CrossRef
43.
Kulldorff M, Davis RL, Kolczak M, et al. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal 2011; 30(1): 58–78CrossRef
44.
Resnic FS, Gross TP, Marinac-Dabic D, et al. Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA 2010; 304(18): 2019–27PubMedCrossRef
45.
Nelson J, Cook A, Yu O. Evaluation of signal detection methods for use in prospective post-licensure medical product safety surveillance. FDA Sentinel Initiative Safety Signal Identification Contract, 2009
46.
Noren GN, Hopstadius J, Bate A, et al. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov 2010; 20(3): 361–87CrossRef
47.
Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf 2011; 20: 292–9PubMedCrossRef
48.
Reisinger SJ, Ryan PB, O’Hara DJ, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assoc 2010 Nov–Dec; 17(6): 652–62PubMedCrossRef
49.
Coloma PM, Trifiró G, Schuemie MJ, et al., on behalf of the EU-ADR consortium. Electronic healthcare databases for active drug safety surveillance: is there enough leverage?. Pharmacoepidemiol Drug Saf. Epub 2012 Feb 8
50.
Seeger JD, Walker AM, Williams PL, et al. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 2003; 92(12): 1447–51PubMedCrossRef
51.
Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005; 14: 465–76PubMedCrossRef
Metadata
Title
Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples
Authors
Mr Peter M. Wahl, MLA, MS
Joshua J. Gagne
Thomas E. Wasser
Debra F. Eisenberg
J. Keith Rodgers
Gregory W. Daniel
Marcus Wilson
Sebastian Schneeweiss
Jeremy A. Rassen
Amanda R. Patrick
Jerry Avorn
Rhonda L. Bohn
Publication date
01-05-2012
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 5/2012
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11594770-000000000-00000

Other articles of this Issue 5/2012

Drug Safety 5/2012 Go to the issue

Leading Article

Defining ‘Surveillance’ in Drug Safety

Review Article

A Benefit-Risk Assessment of Dapoxetine in the Treatment of Premature Ejaculation

Original Research Article

A Cohort Study Exploring Determinants of Safety-Related Regulatory Actions for Biopharmaceuticals

Short Communication

Promoting Spontaneous Adverse Drug Reaction Reporting in Hospitals Using a Hyperlink to the Online Reporting Form

Systematic Review

Impact of Safety-Related Regulatory Action on Clinical Practice

Original Research Article

A Pharmacoepidemiological Network Model for Drug Safety Surveillance